A Phase 1, Open Label, Dose Escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MG1102 in Patients with Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 28 Mar 2017
At a glance
- Drugs MG 1102 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- 28 Mar 2017 Status changed from discontinued to completed, according to the results published in the Investigational New Drugs
- 28 Mar 2017 Results published in the Investigational New Drugs
- 25 Nov 2015 Status changed from active, no longer recruiting to discontinued, according to ClinicalTrials.gov record.